Nifedipine therapy for stable angina pectoris: preliminary results of effects on angina frequency and treadmill exercise response.
Nifedipine therapy for stable angina pectoris: preliminary results of effects on angina frequency and treadmill exercise response.
复制标题
硝苯地平治疗稳定型心绞痛：对心绞痛频率和跑步机运动反应影响的初步结果。
DOI：
10.1016/0002-9149(79)90202-9
复制
发表时间：
1979
影响因子：
2.8
通讯作者：
Robert Zelis
中科院分区：
文献类型：
--
作者：
Ralph M. Moskowitz;Paul A. Piccini;Gerald V. Nacarelli;Robert Zelis
10例继发于动脉粥样硬化性冠状动脉疾病的稳定型心绞痛患者在6周内以单盲方式接受硝苯地平（10 mg和20 mg，口服，每日3次，每次2周）或安慰剂（2周）。1例患者被排除，因为他在接受安慰剂时发生了夜间和静息心绞痛。其余9名患者的心绞痛发作频率从安慰剂治疗期间的11.2 ± 2.2（平均值±平均值的标准误差）/患者/周降至硝苯地平10 mg治疗期间的7.1 ± 1.6和硝苯地平20 mg治疗期间的6.3 ±1.7（两种剂量的活性药物与安慰剂相比P< 0.05）。硝酸甘油的消耗量也同样从8.9 ± 2.3片/周（安慰剂）下降到10 mg硝苯地平治疗期间的4.8 ± 1.4片/周和20 mg硝苯地平治疗期间的4.2 ± 1.2片/周（两种剂量的药物与安慰剂相比P< 0.05）。踏车运动的持续时间从368 ± 50秒（安慰剂）增加到硝苯地平10 mg剂量的471 ± 72秒和20 mg剂量的522 ± 79秒（两种剂量与安慰剂相比P< 0.05）。安慰剂治疗期和活性药物治疗期的最大S-T段移位和心率×收缩压乘积无差异。在随后的安慰剂和硝苯地平的双盲、随机交叉治疗中进行的踏车运动显示，硝苯地平治疗后的运动持续时间（524 ± 49秒）比安慰剂治疗后的运动持续时间（462 ± 52秒）增加（P< 0.005），但最大S-T移位和心率×收缩压乘积没有差异。硝苯地平的副作用轻微，易于耐受。结果似乎表明，硝苯地平缩短运动时间，降低心率×收缩压乘积在给定的工作负荷，可能是在类似的方式，长效硝酸盐治疗。
Ten patients with stable angina pectoris secondary to atherosclerotic coronary artery disease received nifedipine (10 mg and 20 mg orally three times daily, each for 2 weeks) or placebo (for 2 weeks) in a single-blind manner during a 6 week period. One patient was excluded because nocturnal and resting angina developed while he was receiving placebo. The frequency of anginal attacks in the remaining nine patients decreased from 11.2 ± 2.2 (mean ± standard error of the mean) per patient per week during administration of placebo to 7.1 ± 1.6 during therapy with nifedipine at 10 mg and to 6.3 ±1.7 during administration of 20 mg of nifedipine (P< 0.05 for both doses of active drug versus placebo). Nitroglycerin consumption similarly decreased from 8.9 ± 2.3 tablets per patient per week (placebo) to 4.8 ± 1.4 tablets during administration of 10 mg of nifedipine and to 4.2 ± 1.2 during therapy with 20 mg of the drug (P< 0.05 for both doses of drug versus placebo). Duration of treadmill exercise increased from 368 ± 50 seconds (placebo) to 471 ± 72 seconds at the 10 mg dose of nifedipine and 522 ± 79 seconds at 20 mg (P< 0.05 for both doses versus placebo). Maximal S-T segment shift and product of heart rate × systolic blood pressure did not differ between the placebo period and that of active drug therapy. Treadmill exercise performed during subsequent double-blind, randomized crossover treatment with placebo and nifedipine revealed increased exercise duration after nifedipine therapy (524 ± 49 seconds) compared with that after placebo (462 ± 52 seconds) (P< 0.005) but, again, maximal S-T shift and the product of heart rate × systolic blood pressure did not differ. Side effects from nifedipine were minor and easily tolerable. The results seem to indicate that nifedipine prolongs exercise time by decreasing heart rate × systolic blood pressure product at a given work load, possibly in a manner similar to that of long-acting nitrate therapy.